Irfan Ahmad and Reshman Shahin
Cancer is one of the most prevalent diseases that affect the major population with each year the frequency is increasing exponentially. Patients with diagnosed cancer are generally treated with the conventional therapies like radiation therapy, chemotherapy. However the survival rate and the life span are known to prolonged, these therapies are quite problematic let alone their detrimental side effects. Gene therapy on the other hand is quite promising since the body’s immune response is not compromised while targeting the cancerous cell. While getting further insights into the complex pathways and mechanisms associated with the development of malignant cells has led to the identification more sophisticated and specified cancer therapies, it nevertheless remains imperative to execute the conventional therapies and the associated anticancer drug molecules. Various characteristic features like less toxicity and ability to induce an immune response make the therapy quite probable for various cancers like pancreatic, ovarian and Glioblastoma. Based on the results obtained from pre-clinical studies in model animals, it has set stage for the commercialization of the human trials. The advantages associated with this therapy for the treatment has started attracting focus to further modify and optimize the procedures for better results.
Partagez cet article
English 
Spanish 
Chinese 
Russian 
German 
Japanese 
Portuguese 
Hindi 